This Is MS Multiple Sclerosis Knowledge & Support Community

Phase II trial with laquinimod in primary progressive MS fails to deliver Active Biotech drug, laquinimod has failed a phase II trial in primary progressive MS. Laquinimod a once-daily oral drug targets neurodegeneration and inflammation with a novel mechanism of action being developed for the treat...

Early medical intervention for the treatment of multiple sclerosis (MS) has been debated by experts for a number of years, with the likes of Gavin Giovannoni a Professor at Barts and the London School of Medicine and Dentistry and many others championing this course of action as a way of preventing ...

Brain inflammation associated with anxiety and depression in RRMS patients A recent study has associated brain inflammation with depression and anxiety in patients with relapsing remitting multiple sclerosis (RRMS). The study, 'Neuroinflammation drives anxiety and depression in relapsing-remitting m...

US researchers discover how rogue immune cells cross the blood-brain barrier to cause MS Different types of immune cells gain access to nerve cells in the brain and spinal cord in different ways, according to multiple sclerosis (MS) researchers based at the University of Illinois in Chicago and the ...

Newly appointed principle investigator to proceed with FDA MS clinical trial of medicinal cannabis MMJ BioScience has hired Dr Bianca Weinstock-Guttman as the principle investigator to lead its patient clinical research into medical marijuana...Read more - http://www.ms-uk.org/newly-appointed-princi...

Roche, the makers of ocrelizumab have today announced that the Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion for the use of ocrelizumab in adults with active relapsing remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS)...Read mo...

Drug company Celgene recently announced results from two phase III trials evaluating the efficacy and safety of the drug ozanimod and is now seeking approval from the U.S Food and Drug Administration (FDA)...Read more - http://www.ms-uk.org/new-ms-drug-ozanimod-seeks-fda-approval https://scontent-lh...

NHS England strikes deal that makes Cladribine available to MS patients tomorrow NHS Chief, Simon Stevens has announce that NHS England has struck a deal to make an innovative treatment for multiple sclerosis (MS) routinely available on the NHS...Read more - http://www.ms-uk.org/nhs-england-strikes-...

New biomarkers could lead to a blood test that can distinguish between relapsing remitting and progressive MS A study led by the University of Sydney's Brain and Mind Centre and Royal Prince Alfred Hospital has revealed unique molecules in the blood of people with multiple sclerosis (MS) that could ...

Caesarean delivery and artificial lactation are associated with early onset MS #ECTRIMS Scientists conducting research into important MS markers have discovered that MS patients born from a caesarean delivery and receiving artificial lactation are more likely to experience the onset of the condition...

A study has shown a significant correlation between the intake of saturated fatty acids and disability and fatigue in MS patients...Read more - http://www.ms-uk.org/fats-and-oils-impact-disability-ms-patients-ectrims https://scontent-lht6-1.xx.fbcdn.net/v/t1.0-9/22090095_1585302771508671_94476839878...

While most people with MS develop neurological impairments over time it is clear that some do not. This has been termed benign MS. Its existence and definition are often debated, so researchers have conducted a study to determine if people with MS can have a ‘benign’ outcome 30 years after first sym...

Children and adolescents with MS experience an 82% lower relapse rate with Gilenya vs. interferon beta-1a #ECTRIMS Pharmaceutical company Novartis has released the full results of a phase III Paradigms study investigating the safety and efficiency of Gilenya (fingolimod) vs. interferon beta-1a in ch...

PRAC recommends further restrictions for MS drug Zinbryta European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) is recommending further restrictions on the use of the multiple sclerosis (MS) drug Zinbryta (daclizumab) following a review of the drug’s effect on the live...

Ocrelizumab lowers risk of upper limb disability progression in PPMS patients #ECTRIMS Upper limb (UL) function impairment is prevalent among patients with primary progressive multiple sclerosis (PPMS) and alters a patient’s quality of life. Researchers set out to evaluate the effect of Ocrelizumab ...